{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:17:32Z","timestamp":1782602252285,"version":"3.54.5"},"reference-count":66,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T00:00:00Z","timestamp":1181174400000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Dialysis"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with stage 5 chronic kidney disease (CKD) including those on dialysis can and do develop osteoporosis. They also develop a wide range of other metabolic bone diseases that may look like osteoporosis when it is defined by either the World Health Organization bone mineral density (BMD) criteria or by the development of fragility fractures. Those dialysis patients with osteoporosis that is due to gonadal hormone deficiency such as postmenopausal osteoporosis, glucocorticoid\u2010induced osteoporosis, or male osteoporosis may benefit from the administration of bisphosphonates (BPs). The challenges lie in the diagnosis of osteoporosis in this population where adynamic, osteomalacic, hyperparathyroid, or aluminum bone disease are also prevalent, with concommitant low BMD and low trauma fractures, but where BPs may be contraindicated. The only secure means to diagnose osteoporosis in this patient population is by quantitative bone histomorphometry demonstrating low trabecular bone volume and disrupted microarchitecture. Once the diagnosis of osteoporosis is established, BPs should be considered for a well\u2010defined brief period of time (e.g., 2\u20133\u2003years), even though there is no evidence for a fracture reduction benefit in this population. If a BP is chosen there may be a need for dose adjustment or slower infusion rates (for the intravenous formulations), as a greater bone retention may occur for these renally cleared agents. While it is unknown what consequences could develop from increased bone retention in patients with little renal function, data are needed if more bone retention of BP might lead to a greater risk of the development of adynamic bone disease and lower bone strength. More data are needed to define the risks and benefits of BPs in patients with stage 5 CKD.<\/jats:p>","DOI":"10.1111\/j.1525-139x.2007.00271.x","type":"journal-article","created":{"date-parts":[[2007,6,7]],"date-time":"2007-06-07T12:02:37Z","timestamp":1181217757000},"page":"186-190","source":"Crossref","is-referenced-by-count":61,"title":["Is There a Role for Bisphosphonates in Chronic Kidney Disease?"],"prefix":"10.1111","volume":"20","author":[{"given":"Paul D.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,6,7]]},"reference":[{"key":"e_1_2_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07088-2"},{"key":"e_1_2_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.14.1344"},{"key":"e_1_2_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200008313430902"},{"issue":"2","key":"e_1_2_2_5_2","first-page":"S106","article-title":"Risedronate shown to be effective and safe in men with osteoporosis in a 2\u2003year double\u2010blind, randomized, placebo\u2010controlled, multicenter study","volume":"17","author":"Boonen S","year":"2006","journal-title":"Osteoporos Int"},{"key":"e_1_2_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807303390502"},{"key":"e_1_2_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K"},{"key":"e_1_2_2_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200311203492114"},{"key":"e_1_2_2_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030050"},{"key":"e_1_2_2_10_2","first-page":"359","volume-title":"Medical Management of Kidney Transplantation","author":"Miller PD","year":"2004"},{"key":"e_1_2_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00816.x"},{"key":"e_1_2_2_12_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1271530"},{"key":"e_1_2_2_13_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030908"},{"key":"e_1_2_2_14_2","first-page":"231","volume-title":"Bisphosphonate Therapy in Acute and Chronic Bone Los","author":"Papapoulos SE","year":"1995"},{"key":"e_1_2_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00062-5"},{"key":"e_1_2_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044241"},{"key":"e_1_2_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(99)00116-7"},{"key":"e_1_2_2_18_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-10-1121"},{"key":"e_1_2_2_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2005.pto_160.x"},{"key":"e_1_2_2_20_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1261164"},{"key":"e_1_2_2_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200310233491721"},{"key":"e_1_2_2_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00071.x"},{"key":"e_1_2_2_23_2","first-page":"115","article-title":"Osteoporosis in end\u2010stage renal disease","volume":"19","author":"Lindberg JS","year":"1999","journal-title":"Semin Nephrol"},{"key":"e_1_2_2_24_2","first-page":"347","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"Goodman WG","year":"1999"},{"key":"e_1_2_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507203330307"},{"key":"e_1_2_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(99)70302-1"},{"issue":"1","key":"e_1_2_2_27_2","first-page":"S274","article-title":"Increased risk of hip fracture in U.S. Medicare end\u2010stage renal disease patients","volume":"12","author":"Gupta A","year":"1997","journal-title":"J Bone Miner Res"},{"key":"e_1_2_2_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2000.00394.x"},{"key":"e_1_2_2_29_2","first-page":"58","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"Burr DB","year":"2003"},{"key":"e_1_2_2_30_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.4.621"},{"key":"e_1_2_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1489-x"},{"key":"e_1_2_2_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02508636"},{"key":"e_1_2_2_33_2","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1210\/jcem.84.6.5710","article-title":"Bone densitometry: the best way to detect osteoporosis and to monitor therapy","volume":"84","author":"Miller PD","year":"1999","journal-title":"J Clin Endocrin Metab"},{"key":"e_1_2_2_34_2","first-page":"100","volume-title":"Primer on Metabolic Bone Disease","author":"Miller PD","year":"2006"},{"key":"e_1_2_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08761-5"},{"key":"e_1_2_2_36_2","first-page":"1","article-title":"Osteoporosis and kidney disease","volume":"6","author":"Miller PD","year":"2005","journal-title":"National Osteoporosis Foundation Clinical Updates"},{"key":"e_1_2_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-005-0021-y"},{"key":"e_1_2_2_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-005-0009-8"},{"key":"e_1_2_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000414"},{"key":"e_1_2_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5001982"},{"key":"e_1_2_2_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_2_42_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.050817"},{"key":"e_1_2_2_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00135.x"},{"key":"e_1_2_2_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544060-00001"},{"key":"e_1_2_2_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/jor.1100030413"},{"key":"e_1_2_2_46_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2000.15.4.613"},{"key":"e_1_2_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(01)00414-8"},{"key":"e_1_2_2_48_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0057"},{"key":"e_1_2_2_49_2","first-page":"2200","article-title":"Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats","volume":"29","author":"Bauss F","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_2_50_2","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040809"},{"key":"e_1_2_2_51_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0952"},{"key":"e_1_2_2_52_2","first-page":"S398","article-title":"Alendronate effects on histomorphometric parameters: is there evidence for over\u2010suppression of bone turnover?","volume":"358","author":"Recker RR","year":"2005","journal-title":"J Bone Miner Res"},{"key":"e_1_2_2_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-004-0039-7"},{"key":"e_1_2_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2005.05.003"},{"key":"e_1_2_2_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-006-0245-6"},{"key":"e_1_2_2_56_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2927"},{"key":"e_1_2_2_57_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.7.1281"},{"key":"e_1_2_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00569.x"},{"key":"e_1_2_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"e_1_2_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"e_1_2_2_61_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"e_1_2_2_62_2","first-page":"1053","article-title":"Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates","volume":"20","author":"Van Posnak C","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_2_63_2","volume-title":"Expert Panel Recommendations: Dental Management of Patients on Oral Bisphosphonate Therapy","author":"Council on Scientific Affairs of the American Dental Association"},{"key":"e_1_2_2_64_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.060712"},{"key":"e_1_2_2_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068157"},{"key":"e_1_2_2_66_2","first-page":"S16","article-title":"Effect of once\u2010yearly infusion of zolendronic acid 5\u2003mg on spine and hip fracture reduction in postmenopausal women with osteoporosis; The Horizon pivotal fracture trial","volume":"21","author":"Black DM","year":"2006","journal-title":"J Bone Miner Res"},{"key":"e_1_2_2_67_2","volume-title":"Osteoporos Int","author":"Miller PD","year":"2007"}],"container-title":["Seminars in Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-139X.2007.00271.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-139X.2007.00271.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:45:54Z","timestamp":1697147154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-139X.2007.00271.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1111\/j.1525-139X.2007.00271.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-139x.2007.00271.x","archive":["Portico"],"relation":{},"ISSN":["0894-0959","1525-139X"],"issn-type":[{"value":"0894-0959","type":"print"},{"value":"1525-139X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}